King's Research Portal

DOI:

[10.1097/j.pain.0000000000002203](https://doi.org/10.1097/j.pain.0000000000002203)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Bannister, K., Kucharczyk, M. W., Graven-Nielsen, T., & Porreca, F. (2021). Introducing descending control of nociception: a measure of diffuse noxious inhibitory controls in conscious animals. *Pain*, 162(7), 1957-1959. <https://doi.org/10.1097/j.pain.0000000000002203>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Introducing descending control of nociception: A measure of diffuse noxious inhibitory controls in conscious animals

Kirsty Bannister^{1*}, Mateusz W. Kucharczyk^{1^}, Thomas Graven-Nielsen², Frank Porreca³

¹ Central Modulation of Pain, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE1 1UL. UK. [^]Joint first authors.

² Center for Neuroplasticity and Pain (CNAP), Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Aalborg, Denmark.

³ Department of Pharmacology, University of Arizona, Tucson, Arizona, AZ 85721. USA.

***Corresponding author**

Address: Institute of Psychiatry, Psychology and Neuroscience, Wolfson CARD, Guy's Campus, King's College London, London, SE1 1UL. UK. Tel.: +44 2078484617; Fax: +44 2078486806. kirsty.bannister@kcl.ac.uk. ORCID ID: 0000-0002-3043-3574

Funding sources: KB is funded by a grant from the Academy of Medical Sciences (RE15263). TGN is a part of the Center for Neuroplasticity and Pain (CNAP) supported by the Danish National Research Foundation (DNRF121). FP is supported by grants from the National Institutes of Health (R01NS106902, R01DA041809, P01DA041307).

Conflicts of interest: KB, MWK, TGN and FP have no conflicts of interest to declare.

Introduction

Ever since Le Bars and colleagues detailed in 1979 that “the activity of convergent dorsal horn neurons could be powerfully inhibited by noxious stimuli applied to various parts of the body” (21), diffuse noxious inhibitory controls (DNIC) have provided basic research a proxy measure of the functionality of a unique descending inhibitory pathway. This *pain inhibits pain*-like phenomenon was originally described in anaesthetised rodents, where it is possible to quantify functional DNIC as a decrease in the peripherally-evoked activity of spinal convergent neurons following application of a conditioning stimulus (CS) (2, 21). Interestingly, such naturally occurring analgesia upon conditioning is also observed in conscious humans (13, 22, 33). Conditioned pain modulation (CPM) is now used to describe the human counterpart of DNIC (35), and CPM paradigms are purported to assess the efficacy of DNIC as a surrogate measure of a descending inhibitory system (9).

Since the translational value of DNIC to CPM may be gauged by the predictive quality of human CPM processing, it is unsurprising that a focus on measuring the expression status of conditioning-activated descending inhibitory controls in behaving animals is coming to the fore (11, 12, 32, 37). An increasing number of human and animal DNIC and CPM studies (Fig. 1) highlights the timely need for consideration of what the appropriate terminology is when describing this effect. In recognition of the fact that only DNIC-like behaviours can so far be measured in wakeful animals, and that it is not appropriate to use CPM to refer to a reduction in pain-related behaviours in pre-clinical research since animal responses are non-verbal, we recommend that the experimental quantification of descending modulatory pathway activation upon conditioning in wakeful animals be referred to as *descending control of nociception* (DCN).

Ensuring that the correct mechanism is cited when considering DNIC versus DCN versus CPM system execution in rodent and human studies is vital. While DNIC expression is maintained under rodent anaesthetic, CPM is measured in wakeful subjects and is thus representative of a complex cognitive input-influenced process. Mechanistically both are activated upon conditioning, but the unconscious processing of neuronal inhibition evidenced during DNIC cannot be assessed during CPM testing, and even though functional CPM likely involves activation of the DNIC pathway it also encompasses a higher cortical centre top-down modulatory circuitry that is influenced by personal attributes. In that vein, when measuring the inhibitory effect of conditioning in behaving animals, it is not only the expression status of the DNIC pathway that is being recorded. Rather now, a DCN effect must also represent a mechanism that encompasses attention to the potentially most damaging insult.

The DCN terminology would allow researchers to acknowledge a clear distinction regarding the subject’s conscious state, where measurement of a functional DNIC response in anaesthetised versus wakeful animals evidently portrays execution of distinct top-down modulatory processes, while also accounting for potential variability in modulatory direction. In addition, an appropriately separate definition would more accurately enable preclinical and clinical DNIC, DCN and CPM comparators in back and forward translational studies.

Key considerations: The unconscious versus conscious state

When mechanistically interrogated in anaesthetised animals, DNIC expression, explicitly referring to the inhibition of wide dynamic range (WDR) neurons upon conditioning, represents the activation of a supra-spinal brainstem nucleus that projects directly to the dorsal horn of the spinal cord (1, 2). In behaving, conscious animals DNIC terminology is applied when quantifying changes in resting nociceptive responses to evoked stimuli (i.e. Randall-Selitto pressure stimulus, von Frey filaments, Hargreaves heat withdrawal threshold) upon injection of an irritant (i.e. capsaicin, formalin) to a distant body region (11, 12, 32, 37) despite the fact that direct spinal neuronal recordings are not made.

DNIC are abolished in rats following spinalisation (14) or cervical block with lidocaine (6), and a lesion to the dorsolateral funiculus (DLF) ipsilateral to an electrophysiologically recorded WDR neuron was previously shown to abolish DNIC expression (34). This suggests that the descending fibres responsible for functional DNIC expression likely travel via the ipsilateral DLF. It is noteworthy that, in wakeful animals, a DLF lesion (including a bilateral lesion) did not abolish hypoalgesia triggered by formalin (CS) injection, suggesting that additional tracts are involved in DNIC expression in behaving rats. Pertinently this highlights the complexity of defining a functional DNIC circuit in wakeful animals where the involvement of other parallel descending tracts is likely (7, 26).

Since it is measured in wakeful humans, CPM represents a complex process whereby cognitive inputs influence top-down sensory processing, including the expression status of inhibitory controls. Unlike DNIC as measured in anaesthetised animals, 'conscious' CPM can evoke pain-inhibitory or facilitatory effects, depending on the context (10, 16, 20, 24, 27, 36). This contextual (cues prone) aspect of CPM likely represents the involvement of at least two opposite neuronal systems. It also suggests that inhibition is a dominant component of unconscious processing that may involve, for example, counterirritation. On that, counterirritation was another term coined to describe a *pain inhibits pain*-like phenomenon, however its mechanistic meaning is less precise since it is not limited to the activation and function of descending inhibitory controls (8, 15, 18). Overwhelmingly, the heterogeneous nature of CPM outputs in the healthy population (10, 16, 20, 23) points to the complexity of the CPM system as compared to the direct functionality of DNIC when quantifying their expression statuses upon conditioning. Having a direct physiological measure of the functionality of an endogenous descending brain to spinal cord pain inhibitory pathway that is independent of an individual's subjective judgment would be the optimal way to truly denote what is, and who possesses, a 'net CPM' effect.

DNIC, DCN and CPM comparators

How comparable are the DNIC, DCN and CPM phenomena and why is it not appropriate to refer to their functionality interchangeably? Clearly, mechanistically speaking, measurement of a functional DNIC response in anaesthetised versus wakeful animals portrays execution of distinct descending processes where

distraction from the sensation evoked by a test stimulus upon conditioning is predicted to be elicited as a minimum. In turn, those descending processes activated in behaving animals will not mirror those associated with a final net CPM effect when acknowledging that wakeful animals do not quantifiably experience human emotions relating to, for example, the *monday blues* or divorce.

In humans cervical spinal cord transection (33) or medullary retro-olive lesions (Wallenberg's syndrome) diminishes CPM expression (13). It is noteworthy that the potential origin of DNIC to pontine nuclei (5, 34) corresponds exactly to the Wallenberg's syndrome-related lesions (4). Human CPM studies pinpoint upper brainstem (19) and cortical (3, 25) brain regions as impacting individual differences in terms of a pain-inhibiting response to a CPM paradigm, where modulatory roles are proposed. Due to the low spatial resolution of fMRI, assigning direct discrete pontine nuclei to CPM expression is so far not possible. Therefore, the precise definition of CPM 'effector' brainstem structures remains to be elucidated. Ideally, they will be defined in animal models such that physiological and pharmacological studies from rodents may be forward translated to humans.

Many studies have successfully studied the underlying functionality of CPM and DNIC paradigms in experimental conditions. Noradrenergic mechanisms explain the beneficial use of monoaminergic manipulation in analgesic therapies in terms of CPM functionality (29, 31, 36) in a manner that back translates (1, 2) and DNIC and CPM deficiencies are evident in varied chronicities (17, 22, 34).

CPM measurements are made in awake humans with the explicit understanding that conscious processing of top-down sensory modulation will impact the final expression status of descending control pathways (that very likely include DNIC). DCN terminology would allow a clear delineation regarding the mechanistic foundation of the effect observed, even when acknowledging that the full circuitry remains equivocal. A role for opiodergic transmission in the anterior cingulate cortex (ACC) in the modulation of DCN expression was recently shown in an animal behavioural model (28). ACC-mediated modulation of DNIC-pathway functionality potentially occurs via a relay in the periaqueductal grey (PAG), as suggested by earlier human functional studies (19), but animal lesion experiments do not support a crucial role for the PAG in DNIC expression (22). However this does not discredit a potential modulatory role in conscious animals, for example upon measurement of DCN. Confirmation of supra-pontine regulation of DCN (i.e. ACC, PAG) in conscious animals requires further investigation. Do CPM and/or DCN expression reflect DNIC pathway functionality and/or a strong (negative or positive) cognitive experience? DCN modulation by forebrain mechanisms is likely (30) and, even when recorded in anaesthetised rodents, the functional expression of DNIC is influenced by subcortical brain regions associated with emotional processing (32).

Thanks to precise genetically encoded tools (i.e. defined discrete neuronal population-targeted optogenetics), the anatomical and physiological definition of the DNIC origin nucleus is likely to soon be resolved. With this in mind, inhibitory/facilitatory control of the DNIC origin nucleus in behaving wakeful animals is on the immediate research horizon. Therefore, a precise terminology that

accurately reflects animal behavioural responses upon its eventual manipulation is imperative.

Concluding

We propose that a distinction between DNIC and CPM should be made in animal studies based on the subject's conscious state (where, interestingly, the conscious state appears to be a source of variability in rodent studies as with human CPM studies). The fact that DNIC are expressed in anaesthetised, unconscious animals highlights its autonomous circuitry. DNIC expression may be modulated in wakeful states by cortical influences, and as such resembles CPM. Using common, precise definitions for DNIC, CPM and DCN phenomena avoids confusion regarding that fact that CPM and DCN may involve DNIC mechanisms, but not the other way around.

References

1. Bannister K, Lockwood S, Goncalves L, Patel R, Dickenson AH. An investigation into the inhibitory function of serotonin in diffuse noxious inhibitory controls in the neuropathic rat. *Eur J Pain*. 2017;21(4):750-60.
2. Bannister K, Patel R, Goncalves L, Townson L, Dickenson AH. Diffuse noxious inhibitory controls and nerve injury: restoring an imbalance between descending monoamine inhibitions and facilitations. *Pain*. 2015;156(9):1803-11.
3. Bogdanov VB, Vigano A, Noirhomme Q, Bogdanova OV, Guy N, Laureys S, Renshaw PF, Dallel R, Phillips, Schoenen J. Cerebral responses and role of the prefrontal cortex in conditioned pain modulation: an fMRI study in healthy subjects. *Behav Brain Res*. 2015;281:187-98.
4. Bouhassira D, Chitour D, Villaneuva L, Le Bars D. The spinal transmission of nociceptive information: modulation by the caudal medulla. *Neuroscience*. 1995;69(3):931-8.
5. Bouhassira D, Villanueva L, Bing Z, le Bars D. Involvement of the subnucleus reticularis dorsalis in diffuse noxious inhibitory controls in the rat. *Brain Res*. 1992;595(2):353-7.
6. Cadden SW, Villanueva L, Chitour D, Le Bars D. Depression of activities of dorsal horn convergent neurones by propriospinal mechanisms triggered by noxious inputs; comparison with diffuse noxious inhibitory controls (DNIC). *Brain Res*. 1983;275(1):1-11.
7. Calvino B. Hypoalgesia induced by counter-irritation is not affected by pCPA pretreatment. *Pharmacol Biochem Behav*. 1990;35(3):731-4.
8. Cervero F, Iggo A, Ogawa H. Nociceptor-driven dorsal horn neurones in the lumbar spinal cord of the cat. *Pain*. 1976;2(1):5-24.
9. Cummins TM, Kucharczyk MM, Graven-Nielsen T, Bannister K. Activation of the descending pain modulatory system using cuff pressure algometry: Back translation from man to rat. *Eur J Pain*. 2020;24(7):1330-8.
10. Cummins TM, McMahon SB, Bannister K. The impact of paradigm and stringent analysis parameters on measuring a net conditioned pain modulation effect: A test, retest, control study. *Eur J Pain*. 2020.
11. Da Silva JT, Tricou C, Zhang Y, Seminowicz DA, Ro JY. Brain networks and endogenous pain inhibition are modulated by age and sex in healthy rats. *Pain*. 2020;161(6):1371-80.
12. Da Silva JT, Zhang Y, Asgar J, Ro JY, Seminowicz DA. Diffuse noxious inhibitory controls and brain networks are modulated in a testosterone-dependent manner in Sprague Dawley rats. *Behav Brain Res*. 2018;349:91-7.
13. De Broucker T, Cesaro P, Willer JC, Le Bars D. Diffuse noxious inhibitory controls in man. Involvement of the spinoreticular tract. *Brain*. 1990;113 (Pt 4):1223-34.
14. Dickenson AH, Le Bars D. Diffuse noxious inhibitory controls (DNIC) involve trigeminothalamic and spinothalamic neurones in the rat. *Exp Brain Res*. 1983;49(2):174-80.
15. Dickenson AH, Le Bars D, Besson JM. Diffuse noxious inhibitory controls (DNIC). Effects on trigeminal nucleus caudalis neurones in the rat. *Brain Res*. 1980;200(2):293-305.
16. Firouzian S, Osborne NR, Cheng JC, Kim JA, Bosma RL, Hemington KS, Rogachov A, Davis KD. Individual variability and sex differences in conditioned pain modulation and the impact of resilience, and conditioning stimulus pain unpleasantness and salience. *Pain*. 2020;161(8):1847-60.
17. Graven-Nielsen T, Izumi M, Petersen KK, Arendt-Nielsen L. User-independent assessment of conditioning pain modulation by cuff pressure algometry. *Eur J Pain*. 2017;21(3):552-61.

18. Handwerker HO, Iggo A, Zimmermann M. Segmental and supraspinal actions on dorsal horn neurons responding to noxious and non-noxious skin stimuli. *Pain*. 1975;1(2):147-65.
19. Harper DE, Ichesco E, Schrepf A, Hampson JP, Clauw DJ, Schmidt-Wilcke T, Harris RE, Harte SE. Resting Functional Connectivity of the Periaqueductal Gray Is Associated With Normal Inhibition and Pathological Facilitation in Conditioned Pain Modulation. *J Pain*. 2018;19(6):635 e1- e15.
20. Kennedy DL, Kemp HI, Wu C, Ridout DA, Rice ASC. Determining Real Change in Conditioned Pain Modulation: A Repeated Measures Study in Healthy Volunteers. *J Pain*. 2020;21(5-6):708-21.
21. Le Bars D, Dickenson AH, Besson JM. Diffuse noxious inhibitory controls (DNIC). I. Effects on dorsal horn convergent neurones in the rat. *Pain*. 1979;6(3):283-304.
22. Le Bars D, Villanueva L, Bouhassira D, Willer JC. Diffuse noxious inhibitory controls (DNIC) in animals and in man. *Patol Fiziol Eksp Ter*. 1992(4):55-65.
23. McPhee M, Graven-Nielsen T. Alterations in Temporal Summation of Pain and Conditioned Pain Modulation Across an Episode of Experimental Exercise-Induced Low Back Pain. *J Pain*. 2019;20(3):264-76.
24. McPhee ME, Vaegter HB, Graven-Nielsen T. Alterations in pronociceptive and antinociceptive mechanisms in patients with low back pain: a systematic review with meta-analysis. *Pain*. 2020;161(3):464-75.
25. Moont R, Crispel Y, Lev R, Pud D, Yarnitsky D. Temporal changes in cortical activation during conditioned pain modulation (CPM), a LORETA study. *Pain*. 2011;152(7):1469-77.
26. Morgan MM, Heinricher MM, Fields HL. Inhibition and facilitation of different nociceptive reflexes by spatially remote noxious stimuli. *J Neurophysiol*. 1994;72(3):1152-60.
27. Nahman-Averbuch H, Leon E, Hunter BM, Ding L, Hershey AD, Powers SW, King CD, Coghill RC. Increased pain sensitivity but normal pain modulation in adolescents with migraine. *Pain*. 2019;160(5):1019-28.
28. Navratilova E, Nation K, Remeniuk B, Neugebauer V, Bannister K, Dickenson AH, Porreca F. Selective modulation of tonic aversive qualities of neuropathic pain by morphine in the central nucleus of the amygdala requires endogenous opioid signaling in the anterior cingulate cortex. *Pain*. 2020;161(3):609-18.
29. Niesters M, Proto PL, Aarts L, Sarton EY, Drewes AM, Dahan A. Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy. *Br J Anaesth*. 2014;113(1):148-56.
30. Nir RR, Yarnitsky D, Honigman L, Granot M. Cognitive manipulation targeted at decreasing the conditioning pain perception reduces the efficacy of conditioned pain modulation. *Pain*. 2012;153(1):170-6.
31. Ossipov MH, Morimura K, Porreca F. Descending pain modulation and chronification of pain. *Curr Opin Support Palliat Care*. 2014;8(2):143-51.
32. Phelps CE, Navratilova E, Dickenson AH, Porreca F, Bannister K. Kappa opioid signaling in the right central amygdala causes hind paw specific loss of diffuse noxious inhibitory controls in experimental neuropathic pain. *Pain*. 2019;160(7):1614-21.
33. Roby-Brami A, Bussel B, Willer JC, Le Bars D. An electrophysiological investigation into the pain-relieving effects of heterotopic nociceptive stimuli. Probable involvement of a supraspinal loop. *Brain*. 1987;110 (Pt 6):1497-508.
34. Villanueva L, Chitour D, Le Bars D. Involvement of the dorsolateral funiculus in the descending spinal projections responsible for diffuse noxious inhibitory controls in the rat. *J Neurophysiol*. 1986;56(4):1185-95.
35. Yarnitsky D. Conditioned pain modulation (the diffuse noxious inhibitory control-like effect): its relevance for acute and chronic pain states. *Curr Opin Anaesthesiol*. 2010;23(5):611-5.

36. Yarnitsky D, Granot M, Nahman-Averbuch H, Khamaisi M, Granovsky Y. Conditioned pain modulation predicts duloxetine efficacy in painful diabetic neuropathy. *Pain*. 2012;153(6):1193-8.
37. Yoneda S, Kasai E, Matsuo M, Tamano R, Sakurai Y, Asaki T, Fujita M. Duloxetine ameliorates the impairment of diffuse noxious inhibitory control in rat models of peripheral neuropathic pain and knee osteoarthritis pain. *Neurosci Lett*. 2020;729:134990.